Journal of Gynecologic Oncology最新文献_第6页

Poor accuracy of endometrial sampling in patients with uterine carcinosarcomas: a nationwide analysis. 子宫内膜取样准确性差的子宫癌肉瘤患者：一个全国性的分析。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-02 DOI: 10.3802/jgo.2025.36.e52

Eveline N B Pham, Caroline B van den Berg, Rachel van Es, Helena C van Doorn, Floris H Groenendijk, Heleen J van Beekhuizen

{"title":"Poor accuracy of endometrial sampling in patients with uterine carcinosarcomas: a nationwide analysis.","authors":"Eveline N B Pham, Caroline B van den Berg, Rachel van Es, Helena C van Doorn, Floris H Groenendijk, Heleen J van Beekhuizen","doi":"10.3802/jgo.2025.36.e52","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e52","url":null,"abstract":"Objective: To determine the accuracy of aspiration biopsy (AB), hysteroscopic biopsy (HB), and dilatation & curettage (D&C) in detecting uterine carcinosarcoma (UCS).Methods: Pathology reports were retrieved from the Dutch Nationwide Pathology Databank PALGA for patients with a certain or suggested diagnosis of UCS in pre- and/or postoperative histology between 2001 and 2021. Patients without available pre- or postoperative pathology reports were excluded. The accuracy measures sensitivity, positive predictive value (PPV), accuracy, and concordance using Cohen's kappa were calculated for AB, D&C, and HB, using postoperative histology as the reference. This was analyzed for 2 scenarios: Analysis A compared samples with a certain or suggested diagnosis of UCS vs. no mention of UCS. Analysis B compared samples with a certain diagnosis of UCS vs those without UCS.Results: The study included 1,481 patients, totaling 1,685 samples. Sensitivity was similar for AB and HB (52.4% and 50.5%, respectively, for analysis A; 45.1% and 42.2% for analysis B). D&C showed the highest sensitivity (70.8% and 64.9% for analysis A and B, respectively). AB had the highest PPV (85.3% and 90.9% for analysis A and B, respectively), HB had the lowest PPV (79.7% and 80.9%, respectively). Accuracy was highest for D&C (44.4%) compared to AB (32.8%) and HB (29.5%). All Cohen's kappa values were below 0.20, indicating poor correlation between preoperative and postoperative diagnoses.Conclusion: The study reveals low accuracy measures across all conventional endometrial sampling techniques, highlighting the need for research to identify markers or tools to diagnose UCS.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Para-aortic lymph node dissection with or without nerve-sparing in gynecological malignancies. 妇科恶性肿瘤的主动脉旁淋巴结清扫术（保留或不保留神经）。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 Epub Date: 2024-07-02 DOI: 10.3802/jgo.2025.36.e9

Qiang Wen, Yuyang Zhu, Haifei Zhou, Li Yang, Feng Shao, Tao Zhu, Zhuyan Shao

{"title":"Para-aortic lymph node dissection with or without nerve-sparing in gynecological malignancies.","authors":"Qiang Wen, Yuyang Zhu, Haifei Zhou, Li Yang, Feng Shao, Tao Zhu, Zhuyan Shao","doi":"10.3802/jgo.2025.36.e9","DOIUrl":"10.3802/jgo.2025.36.e9","url":null,"abstract":"Objective: Para-aortic lymph node dissection (PALND) is a widely used treatment that causes many complications. This study is to evaluate the efficacy and safety of nerve-sparing para-aortic lymph node dissection (NSPALND) by comparing it with conventional PALND in gynecological malignancies and to prove whether locating the superior hypogastric plexus (SHP) can help reveal the para-aortic nerves.Methods: This is a retrospective study of the patients who underwent para-aortic lymphadenectomy from January 2020 to December 2022 at Zhejiang Cancer Hospital. All of them were divided into NSPALND and PALND groups according to whether or not nerve-sparing was performed. The surgical, functional and oncological outcomes were evaluated.Results: There were 43 patients enrolled, of which, 20 patients underwent NSPALND and 23 patients underwent PALND. The para-aortic nerves were successfully revealed by locating the SHP in all 20 cases of NSPALND. The post-operative anal exhaust time in the NSPALND group was significantly shorter than that in the PALND group (2.5 vs. 4 days, p=0.006), and the incidence of acute intestinal obstruction in the NSPALND group was significantly lower than that in the PALND group (10% vs. 39%, p=0.029). There was no difference between the two groups in terms of catheterization duration, urinary retention, dysuria, as well as the number of lymph nodes removed and the para-aortic recurrence rate.Conclusion: NSPALND can significantly reduce the rate of acute intestinal obstruction and improve post-operative intestinal function. Locating the SHP and using it as an anatomical landmark to reveal the para-aortic nerves is feasible. Its exact clinical value needs to be further studied.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e9"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis. 晚期子宫内膜癌患者的免疫疗法加化疗：成本效益分析。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 Epub Date: 2024-06-03 DOI: 10.3802/jgo.2025.36.e6

Youwen Zhu, Kun Liu, Hong Zhu

{"title":"Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis.","authors":"Youwen Zhu, Kun Liu, Hong Zhu","doi":"10.3802/jgo.2025.36.e6","DOIUrl":"10.3802/jgo.2025.36.e6","url":null,"abstract":"Objective: Pembrolizumab and dostarlimab are immune checkpoint inhibitors that target programmed death receptor 1 (PD-1). Combination anti-PD-1 regimens have been shown to exhibit favorable survival benefits when treating advanced endometrial cancer (EC). Which treatment was preferable will need to be confirmed by a cost-effectiveness comparison between them.Methods: Based on patient and clinical parameters from RUBY and NRG-GY018 phase III randomized controlled trials, the Markov model with a 20-year time horizon was established to evaluate the cost-effectiveness of dostarlimab plus chemotherapy (DC), pembrolizumab plus chemotherapy (PC), and chemotherapy alone (C) treatment for patients with mismatch repair-proficient microsatellite-stable (pMMR-MSS) and mismatch repair-deficient microsatellite instability-high (dMMR-MSI-H) advanced EC from the American payers' perspective. The main results include total cost, life-years (LYs), quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) at a $150,000/QALY of willingness-to-pay.Results: In the pMMR-MSS population, DC, PC, and C produced costs (QALYs) of $99,205 (3.02), $322,530 (3.25), and $421,923 (4.40), resulting in corresponding ICERs of $974,177/QALY (PC vs. C), $234,527/QALY (DC vs. C), $86,671/QALY (DC vs. PC), respectively; In the dMMR-MSI-H population, DC, PC, and C obtained costs (QALYs) of $120,177 (5.73), $691,399 (8.43), and $708,787 (11.26), yielding ICERs of $266,423/QALY (PC vs. C), $135,165/QALY (DC vs. C), $7,866/QALY (DC vs. PC), respectively.Conclusion: In the US, DC was a more cost-effective treatment than PC for patients with advanced EC irrespective of MMR status. However, compared to C, DC was associated with more cost-effectiveness in the dMMR-MSI-H population.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e6"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of cisplatin combined with paclitaxel concurrent radiotherapy in patients with locally advanced cervical squamous cell carcinoma. 顺铂联合紫杉醇同步放疗治疗局部晚期宫颈鳞状细胞癌的疗效和安全性。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 DOI: 10.3802/jgo.2025.36.e10

Tao Feng, Yuxin Zhang, Guanghao Zheng, Xiaojuan Lv, Dingding Yan, Yue Feng, Hanmei Lou

{"title":"Efficacy and safety of cisplatin combined with paclitaxel concurrent radiotherapy in patients with locally advanced cervical squamous cell carcinoma.","authors":"Tao Feng, Yuxin Zhang, Guanghao Zheng, Xiaojuan Lv, Dingding Yan, Yue Feng, Hanmei Lou","doi":"10.3802/jgo.2025.36.e10","DOIUrl":"10.3802/jgo.2025.36.e10","url":null,"abstract":"Objective: This study aimed to compare outcomes and adverse events of patients with locally advanced cervical cancer (LACC) undergoing concurrent chemoradiotherapy (CCRT) with cisplatin single-agent chemotherapy vs. CCRT with cisplatin combined with paclitaxel dual-agent therapy. The primary outcomes are overall survival (OS), progression-free survival (PFS), local recurrence (LR), distant metastasis (DM) and the occurrence of adverse events.Methods: This retrospective cohort study included patients with FIGO 2009 stage IB1-IVA cervical squamous cell carcinoma undergoing radical CCRT. Patients were divided into groups A and B, treatment outcomes were compared between the two groups after 1:1 proportional propensity score matching.Results: Medical records of 1,203 patients were reviewed and 572 patients were finally included for propensity score matching. After propensity score matching, 121 pairs of patients were selected for analysis. The OS, PFS, LR and DM rates were 78.5% and 83.5% (p=0.417), 73.3% and 78.5% (p=0.312), 6.6% and 2.5% (p=0.123), 19% and 15.7% (p=0.497) for groups A and B, respectively. Further subgroup analysis according to stage and lymph node metastatic status showed no difference in survival between the two groups. The incidence of grade 3-4 acute haematological toxicities was different between the two groups (p<0.05).Conclusion: Cisplatin combined with paclitaxel CCRT couldn't improve the survival rates of patients with LACC. However, the hematological toxicity of combination chemotherapy is more severe but controllable. Cisplatin single-agent therapy remains the first choice for CCRT. Further prospective studies are indicated to provide evidence for the efficacy of cisplatin plus paclitaxel in dual-agent concurrent therapy.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":"36 1","pages":"e10"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers. 2024年的妇科肿瘤学：宫颈癌、子宫癌和卵巢癌的突破性试验和不断发展的治疗策略。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 DOI: 10.3802/jgo.2025.36.e72

Sung Jong Lee, Ji Geun Yoo, Jin Hwi Kim, Jeong-Yeol Park, Jung-Yun Lee, Yoo-Young Lee, Dong Hoon Suh

引用次数: 0

HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma. HER2阴性或低表达是I/II期子宫癌肉瘤患者的不利预后因素。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 Epub Date: 2024-07-02 DOI: 10.3802/jgo.2025.36.e14

Chiharu Mizoguchi, Tadaaki Nishikawa, Hiroshi Yoshida, Masanori Yasuda, Tomoyasu Kato, Kosei Hasegawa, Kan Yonemori

{"title":"HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma.","authors":"Chiharu Mizoguchi, Tadaaki Nishikawa, Hiroshi Yoshida, Masanori Yasuda, Tomoyasu Kato, Kosei Hasegawa, Kan Yonemori","doi":"10.3802/jgo.2025.36.e14","DOIUrl":"10.3802/jgo.2025.36.e14","url":null,"abstract":"Objective: Uterine carcinosarcoma (UCS) is uncommon high-grade endometrial cancer with limited treatment options. We evaluated the prognostic significance of human epidermal growth factor receptor 2 (HER2) expression and HER2 gene amplification within large cohorts of UCS, and clarify clinicopathologic characteristics of HER2-low UCS.Methods: We examined HER2 protein expression in 148 patients of UCS using in vivo diagnostic HER2 immunohistochemistry (IHC) kits and HER2 gene amplification using fluorescence in situ hybridization (FISH) in 72 patients.Results: HER2 IHC score was evaluated according to the latest American Society of Clinical Oncology/College of American Pathologists criteria for gastric cancer, which was negative in 41 patients, low expression of 1+ was observed in 57 patients, and HER2 high expression was observed in 50 patients (2+ in 38 and 3+ in 12 patients). There was no significant statistical difference in clinicopathological characteristics based on HER2 protein expression status. HER2 negative and low expression compared to high expression revealed poor overall survival in stage I/ II. The concordance between IHC and FISH results were relatively low compared to other cancer types (HER2 IHC score 1+, 2+, and 3+ were 5%, 15%, and 50%), and combining these results was not efficient as a prognostic factor in UCS. In contrast, the HER2 IHC score alone was a prognostic factor in stage I/II UCS. HER2 low group did not show specific clinicopathologic features.Conclusion: Since the HER2 IHC score low in advanced UCS is a predictive factor, stratification of UCS using HER2 IHC score for HER2 IHC score low group and developing adjuvant therapy may be proposed in the near future.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e14"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ATF1 regulates MAL2 expression through inhibition of miR-630 to mediate the EMT process that promotes cervical cancer cell development and metastasis. ATF1 通过抑制 miR-630 来调节 MAL2 的表达，从而介导促进宫颈癌细胞发育和转移的 EMT 过程。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 Epub Date: 2024-07-02 DOI: 10.3802/jgo.2025.36.e11

Yanming Cao, Yuping Peng, Youqun Tang

{"title":"ATF1 regulates MAL2 expression through inhibition of miR-630 to mediate the EMT process that promotes cervical cancer cell development and metastasis.","authors":"Yanming Cao, Yuping Peng, Youqun Tang","doi":"10.3802/jgo.2025.36.e11","DOIUrl":"10.3802/jgo.2025.36.e11","url":null,"abstract":"Objective: The existence of activating transcription factor 1 (ATF1) could be employed as a clinical marker in the context of cervical cancer development, although its specific mechanism has not been fully clarified.Methods: To evaluate the presence of ATF1, miR-630, and myelin and lymphocyte protein 2 (MAL2) in cervical malignancies, we conducted quantitative reverse transcription polymerase chain reaction, immunohistochemistry, and Western blot assays; further studied the expansion, migration, invasion and epithelial-mesenchymal transition (EMT) of cervical carcinoma cells using colony formation assay, transwell, loss cytometry, Western blot. Chromatin immunoprecipitation (ChIP) and RNA immunoprecipitation (RIP) were used to verify that ATF1 could directly transcriptionally repress miR-630; dual luciferase reporter assay and RIP assay were employed to confirm that miR-630 targeted to repress MAL2.Results: In cervical cancer cases, elevated ATF1 expression and reduced miR-630 expression were detected, displaying a negative relationship between them. Inhibition of ATF1 hindered the growth, migration, infiltration, and EMT in cervical carcinoma cells, while upregulation of miR-630 mitigated the aggressive characteristics of these cells. ATF1 was found to transcriptionally repress miR-630 by TransmiR and ALGGEN prediction and ChIP validation. MicroRNA modulates gene expression and affects cancer progression, and we discovered that miR-630 regulates cancer progression by targeting and inhibiting MAL2.Conclusion: ATF1, which modulates the miR-630/MAL2 pathway, affects the EMT process and cervical carcinoma cell growth and spread. Therefore, ATF1 may serve as a promising marker and treatment target for cervical malignancies intervention.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e11"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical practice guidelines for uterine corpus cancer: an update to the Korean Society of Gynecologic Oncology guidelines. 子宫体癌的临床实践指南：韩国妇科肿瘤学会指南的更新。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 DOI: 10.3802/jgo.2025.36.e71

Woo Yeon Hwang, Ju-Hyun Kim, Joseph J Noh, Min-Hyun Baek, Min Chul Choi, Yong Jae Lee, Maria Lee, Dong Hoon Suh, Yong Beom Kim, Dae-Yeon Kim

{"title":"Clinical practice guidelines for uterine corpus cancer: an update to the Korean Society of Gynecologic Oncology guidelines.","authors":"Woo Yeon Hwang, Ju-Hyun Kim, Joseph J Noh, Min-Hyun Baek, Min Chul Choi, Yong Jae Lee, Maria Lee, Dong Hoon Suh, Yong Beom Kim, Dae-Yeon Kim","doi":"10.3802/jgo.2025.36.e71","DOIUrl":"10.3802/jgo.2025.36.e71","url":null,"abstract":"The Korean Society of Gynecologic Oncology has updated its clinical practice guidelines for endometrial cancer to incorporate advancements in recent high-quality randomized controlled trials. These guidelines address evolving treatment paradigms, and are tailored to the Korean medical context. Key updates include a strong recommendation for doxorubicin/trabectedin combination therapy in metastatic or recurrent unresectable leiomyosarcoma based on the significant survival benefits demonstrated in a randomized controlled trial. For advanced or recurrent endometrial cancer, immune checkpoint inhibitors combined with chemotherapy have received strong recommendations, owing to their proven efficacy and increased accessibility in Korea. Conditional recommendations were made for combination therapies involving durvalumab and olaparib, reflecting their potential benefits, but acknowledging regulatory and accessibility constraints. These guidelines aim to provide evidence-based, practical strategies to optimize care for patients with endometrial cancer while addressing unmet clinical needs and adapting global advancements to Korea's healthcare environment.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":"36 1","pages":"e71"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CHIPOR, HORSE, and beyond: unraveling the role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. CHIPOR， HORSE及其他：揭示腹腔热化疗（HIPEC）在卵巢癌中的作用。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 DOI: 10.3802/jgo.2025.36.e73

Myong Cheol Lim

引用次数: 0

Prophylactic salpingectomy as a preventative strategy for ovarian cancer in the general population: a systematic review and meta-analysis. 在普通人群中，预防性输卵管切除术作为卵巢癌的预防策略：一项系统回顾和荟萃分析。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2025-01-01 DOI: 10.3802/jgo.2025.36.e8

Yuting Tang, Haiying Sun, Peiying Fu, Ting Zhou, Ronghua Liu

{"title":"Prophylactic salpingectomy as a preventative strategy for ovarian cancer in the general population: a systematic review and meta-analysis.","authors":"Yuting Tang, Haiying Sun, Peiying Fu, Ting Zhou, Ronghua Liu","doi":"10.3802/jgo.2025.36.e8","DOIUrl":"10.3802/jgo.2025.36.e8","url":null,"abstract":"Objective: The impact of prophylactic salpingectomy on the prevention of epithelial ovarian cancer (EOC) remains unclear, particularly in Asian populations where data is lacking. In this systematic review and meta-analysis study, we sought to assess whether prophylactic salpingectomy could reduce the incidence of ovarian cancer in the general population of multiple ethnicities.Methods: A systematic review and meta-analysis were conducted using PubMed/MEDLINE, EMBASE, the Cochrane Library, and Web of Science to assess the effectiveness of salpingectomy, bilateral salpingectomy (BS), and unilateral salpingectomy (US) in reducing the risk of EOC and evaluating postoperative outcomes.Results: The final analyses included 6 eligible trials (5,747,056 patients), including 1 cohort study and 5 case-control studies. The analyses of these studies demonstrated that women who underwent salpingectomy had a significantly reduced risk of EOC compared to those who did not receive salpingectomy (odds ratio [OR]=0.63; 95% confidence interval [CI]=0.45-0.89; p=0.007). Five studies (5,746,469 patients) indicated a significant reduction in EOC risk among patients who underwent BS (OR=0.48; 95% CI=0.33-0.69; p<0.001). On the other hand, in the analysis of 4 studies (5,745,887 patients) that examined US, the association with EOC risk was not significant despite the protective trend (OR=0.82; 95% CI=0.64-1.06; p=0.12).Conclusion: Our results indicate BS is an effective strategy for reducing the risk of sporadic EOC, but the results did not lead to the same conclusion for patients who underwent US. When a candidate or patient is undergoing a hysterectomy or has other benign diseases, prophylactic BS may be a safe surgical procedure that carries future benefits in terms of EOC risk.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":"36 1","pages":"e8"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0